Analyst Ratings for Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received somewhat bullish ratings from four analysts in the last quarter, with an average price target of $104.5, implying an upside from the current price of $36.41. This average represents a 2.03% decrease from the previous average price target of $106.67.
November 03, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has received somewhat bullish ratings from four analysts, with an average price target of $104.5, implying an upside from the current price.
The somewhat bullish ratings from analysts suggest a positive outlook for Ultragenyx Pharmaceutical. The average price target of $104.5, which is significantly higher than the current price, indicates potential for growth. However, the decrease in the average price target from the previous quarter suggests some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100